{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:04:24Z","timestamp":1791428664805,"version":"4.3.3"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"uniQure biopharma BV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Huntington\u2019s disease (HD) is a fatal neurodegenerative disease caused by a trinucleotide repeat expansion in exon 1 of the huntingtin gene (HTT) that results in toxic gain of function and cell death. Despite its monogenic cause, the pathogenesis of HD is highly complex, and increasing evidence indicates that, in addition to the full-length (FL) mutant HTT protein, the expanded exon 1 HTT (HTTexon1) protein that is translated from the HTT1a transcript generated by aberrant splicing is prone to aggregate and might contribute to HD pathology. This finding suggests that reducing the expression of HTT1a might achieve a greater therapeutic benefit than targeting only FL mutant HTT. Conversely, strategies that exclusively target FL HTT might not completely prevent the pathogenesis of HD.<\/jats:p>\n                  <jats:p>We have developed an engineered microRNA targeting the HTT exon 1 sequence (miHTT), delivered via adeno-associated virus serotype 5 (AAV5). The target sequence of miHTT is present in both FL HTT and HTT1a transcripts. Preclinical studies with AAV5-miHTT have demonstrated efficacy in several rodent and large animal models by reducing FL HTT mRNA and protein and rescuing HD-like phenotypes and have been the rationale for phase I\/II clinical studies now ongoing in the USA and Europe. In the present study, we evaluated the ability of AAV5-miHTT to reduce the levels of aberrantly spliced HTT1a mRNA and the HTTexon1 protein in the brain of two mouse models of HD (heterozygous zQ175 knock-in mice and humanized Hu128\/21 mice).<\/jats:p>\n                  <jats:p>Polyadenylated HTT1a mRNA and HTTexon1 protein were detected in the striatum and cortex of heterozygous zQ175 knock-in mice, but not in wild-type littermate control mice. Intrastriatal administration of AAV5-miHTT resulted in dose-dependent expression of mature miHTT microRNA in cortical brain regions, accompanied by significant lowering of both FL HTT and HTT1a mRNA expression at 2 months postinjection. Mutant HTT and HTTexon1 protein levels were also significantly reduced in the striatum and cortex of heterozygous zQ175 knock-in mice at 2 months after AAV5-miHTT treatment and in humanized Hu128\/21 mice 7 months post-treatment. The effects were confirmed in primary Hu128\/21 neuronal cultures.<\/jats:p>\n                  <jats:p>These results demonstrate that AAV5-miHTT gene therapy is an effective approach to lower both FL HTT and the pathogenic HTTexon1 levels, which could potentially have an additive therapeutic benefit in comparison to other HTT-targeting modalities.<\/jats:p>","DOI":"10.1093\/brain\/awae266","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T20:25:13Z","timestamp":1724012713000},"page":"4043-4055","source":"Crossref","is-referenced-by-count":32,"title":["Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models"],"prefix":"10.1093","volume":"147","author":[{"given":"Marina","family":"Sogorb-Gonzalez","sequence":"first","affiliation":[{"name":"Department of Research & Development, uniQure Biopharma BV , Amsterdam 1105 BP ,","place":["The Netherlands"]},{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden, 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-6447","authenticated-orcid":false,"given":"Christian","family":"Landles","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3877-455X","authenticated-orcid":false,"given":"Nicholas S","family":"Caron","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia , Vancouver, BC, V5Z 4H4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Stam","sequence":"additional","affiliation":[{"name":"Department of Research & Development, uniQure Biopharma BV , Amsterdam 1105 BP ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-3179","authenticated-orcid":false,"given":"Georgina","family":"Osborne","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Hayden","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia , Vancouver, BC, V5Z 4H4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Howland","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation , Princeton, NJ 08540 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"van Deventer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden, 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-6305","authenticated-orcid":false,"given":"Gillian P","family":"Bates","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, Department of Neurodegenerative Disease and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9377-2880","authenticated-orcid":false,"given":"Astrid","family":"Vall\u00e8s","sequence":"additional","affiliation":[{"name":"Department of Research & Development, uniQure Biopharma BV , Amsterdam 1105 BP ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Research & Development, uniQure Biopharma BV , Amsterdam 1105 BP ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,18]]},"reference":[{"key":"2024121302181518500_awae266-B1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"2024121302181518500_awae266-B2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: The integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"key":"2024121302181518500_awae266-B3","first-page":"143","volume-title":"Handbook of clinical neurology","author":"Stoyas","year":"2018"},{"key":"2024121302181518500_awae266-B4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jmcb\/mjq005","article-title":"Polyglutamine diseases: Where does toxicity come from? What is toxicity? Where are we going?","volume":"2","author":"Takahashi","year":"2010","journal-title":"J Mol Cell Biol"},{"key":"2024121302181518500_awae266-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington\u2019s disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp Neurol"},{"key":"2024121302181518500_awae266-B6","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: Relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J Neurosci"},{"key":"2024121302181518500_awae266-B7","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"2024121302181518500_awae266-B8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"key":"2024121302181518500_awae266-B9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"key":"2024121302181518500_awae266-B10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"2024121302181518500_awae266-B11","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3390\/ijms21062146","article-title":"Huntingtin lowering strategies","volume":"21","author":"Marxreiter","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024121302181518500_awae266-B12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of Huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"2024121302181518500_awae266-B13","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024121302181518500_awae266-B14","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2024121302181518500_awae266-B15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat Med"},{"key":"2024121302181518500_awae266-B16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol Ther"},{"key":"2024121302181518500_awae266-B17","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci Transl Med"},{"key":"2024121302181518500_awae266-B18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"2024121302181518500_awae266-B19","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J Biol Chem"},{"key":"2024121302181518500_awae266-B20","doi-asserted-by":"crossref","first-page":"167222","DOI":"10.1016\/j.jmb.2021.167222","article-title":"The Nt17 domain and its helical conformation regulate the aggregation, cellular properties and neurotoxicity of mutant huntingtin exon 1","volume":"433","author":"Vieweg","year":"2021","journal-title":"J Mol Biol"},{"key":"2024121302181518500_awae266-B21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2005.07.014","article-title":"Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin","volume":"21","author":"Tanaka","year":"2006","journal-title":"Neurobiol Dis"},{"key":"2024121302181518500_awae266-B23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/hmg\/ddu504","article-title":"Comparative study of naturally occurring Huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington\u2019s disease","volume":"24","author":"Barbaro","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/hmg\/ddaa001","article-title":"Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT","volume":"29","author":"Chongtham","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"2024121302181518500_awae266-B26","first-page":"141","article-title":"Emerging therapies for Huntington\u2019s disease\u2014Focus on N-terminal huntingtin and huntingtin exon 1","volume":"16","author":"van der Bent","year":"2022","journal-title":"Biologics"},{"key":"2024121302181518500_awae266-B27","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024121302181518500_awae266-B28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","article-title":"The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients","volume":"7","author":"Neueder","year":"2017","journal-title":"Sci Rep"},{"key":"2024121302181518500_awae266-B29","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/s41467-018-06281-3","article-title":"Regulatory mechanisms of incomplete huntingtin mRNA splicing","volume":"9","author":"Neueder","year":"2018","journal-title":"Nat Commun"},{"key":"2024121302181518500_awae266-B30","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","article-title":"Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset","volume":"18","author":"Swami","year":"2009","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B31","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/hmg\/ddaa139","article-title":"Patterns of CAG repeat instability in the central nervous system and periphery in Huntington\u2019s disease and in spinocerebellar ataxia type 1","volume":"29","author":"Pinto","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther"},{"issue":"1):","key":"2024121302181518500_awae266-B33","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2024121302181518500_awae266-B34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024121302181518500_awae266-B35","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1093\/brain\/awac458","article-title":"AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington\u2019s disease mouse model","volume":"146","author":"Thomson","year":"2023","journal-title":"Brain"},{"key":"2024121302181518500_awae266-B36","doi-asserted-by":"crossref","first-page":"eabb8920","DOI":"10.1126\/scitranslmed.abb8920","article-title":"Widespread and sustained target engagement in Huntington\u2019s disease minipigs upon intrastriatal microRNA-based gene therapy","volume":"13","author":"Valles","year":"2021","journal-title":"Sci Transl Med"},{"key":"2024121302181518500_awae266-B37","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol Ther"},{"key":"2024121302181518500_awae266-B38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/brainsci11020129","article-title":"Intrastriatal administration of AAV5-MIHTT in non-human primates and rats is well tolerated and results in MIHTT transgene expression in key areas of Huntington disease pathology","volume":"11","author":"Spronck","year":"2021","journal-title":"Brain Sci"},{"key":"2024121302181518500_awae266-B39","doi-asserted-by":"crossref","first-page":"ddx021","DOI":"10.1093\/hmg\/ddx021","article-title":"A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles","volume":"26","author":"Southwell","year":"2017","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B40","doi-asserted-by":"crossref","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: ZQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS One"},{"key":"2024121302181518500_awae266-B41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12665\/J133.Lubelski","article-title":"Insect cell-based recombinant adeno-associated virus production: Molecular process optimization","volume":"13","author":"Lubelski","year":"2014","journal-title":"Bioprocess J"},{"key":"2024121302181518500_awae266-B42","doi-asserted-by":"crossref","first-page":"e50717","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PLoS One"},{"key":"2024121302181518500_awae266-B43","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B44","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/dds037","article-title":"Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice","volume":"21","author":"Pouladi","year":"2012","journal-title":"Hum Mol Genet"},{"key":"2024121302181518500_awae266-B45","doi-asserted-by":"crossref","first-page":"16137","DOI":"10.1038\/s41598-019-52411-2","article-title":"Extensive expression analysis of Htt transcripts in brain regions from the zQ175 HD mouse model using a QuantiGene Multiplex assay","volume":"9","author":"Papadopoulou","year":"2019","journal-title":"Sci Rep"},{"key":"2024121302181518500_awae266-B46","doi-asserted-by":"crossref","first-page":"fcad010","DOI":"10.1093\/braincomms\/fcad010","article-title":"Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches","volume":"5","author":"Smith","year":"2023","journal-title":"Brain Commun"},{"key":"2024121302181518500_awae266-B47","doi-asserted-by":"crossref","first-page":"fcaa231","DOI":"10.1093\/braincomms\/fcaa231","article-title":"Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms","volume":"3","author":"Landles","year":"2021","journal-title":"Brain Commun"},{"key":"2024121302181518500_awae266-B48","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1093\/brain\/awac241","article-title":"Alternative processing of human HTT mRNA with implications for Huntington\u2019s disease therapeutics","volume":"145","author":"Fienko","year":"2022","journal-title":"Brain"},{"key":"2024121302181518500_awae266-B49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther"},{"key":"2024121302181518500_awae266-B50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.12.464132","article-title":"Hippocampus-striatum wiring diagram revealed by directed stepwise polysynaptic tracing","author":"Du","journal-title":"bioRxiv"},{"key":"2024121302181518500_awae266-B51","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024121302181518500_awae266-B52","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","article-title":"Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease","volume":"104","author":"Wright","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2024121302181518500_awae266-B53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaneurol.2020.0299","article-title":"Huntingtin-lowering therapies for Huntington disease: A review of the evidence of potential benefits and risks","volume":"77","author":"Leavitt","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024121302181518500_awae266-B54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024121302181518500_awae266-B55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","article-title":"Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease","volume":"15","author":"Martier","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024121302181518500_awae266-B56","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","article-title":"Nuclear localization of Huntingtin mRNA is specific to cells of neuronal origin","volume":"24","author":"Didiot","year":"2018","journal-title":"Cell Rep"},{"key":"2024121302181518500_awae266-B57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/nat.2024.0027","article-title":"mRNA nuclear clustering leads to a difference in mutant huntingtin mRNA and protein silencing by siRNAs in vivo","volume":"34","author":"Allen","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"2024121302181518500_awae266-B58","doi-asserted-by":"crossref","first-page":"1097491","DOI":"10.3389\/fimmu.2023.1097491","article-title":"Recent advances in the functional explorations of nuclear microRNAs","volume":"14","author":"Hu","year":"2023","journal-title":"Front Immunol"},{"key":"2024121302181518500_awae266-B59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3724\/abbs.2023268","article-title":"Noncanonical functions of microRNAs in the nucleus: Noncanonical functions of microRNAs in the nucleus","volume":"56","author":"Gu","year":"2024","journal-title":"Acta Biochim Biophys Sin (Shanghai)"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae266\/59760427\/awae266.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/12\/4043\/60939456\/awae266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/12\/4043\/60939456\/awae266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T21:18:41Z","timestamp":1734038321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/147\/12\/4043\/7735411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,18]]},"published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae266","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,18]]}}}